Literature DB >> 8653920

Why is the laboratory an afterthought for managed care organizations?

R W Forsman1.   

Abstract

Market forces have dramatically influenced the environment in which healthcare is delivered, but these changes do not need to be interpreted negatively by community laboratorians. Only total vertical integration of laboratory medicine can control episode-of-care cost. Opportunities also exist for horizontal integration with community partners to provide geographical coverage and to compete favorably for managed care contracts. Lowering cost through "economies of scale" may apply to the procurement of supplies and equipment, but the delivery of services must be considered in the context of their overall effect on episode-of-care cost. Laboratory services may make up 5% of a hospital's budget but leverage 60-70% of all critical decision-making such as admittance, discharge, and medication. Laboratory outreach can help the medical center's financial stability by: (a) providing tests and service that can reduce or avoid a hospital stay; (b) using the additional volume of testing to distribute existing fixed costs and lower unit cost; and (c) adding revenue as a direct contribution to margin. To successfully compete for contracted managed care services, the laboratory must network with other providers to demonstrate comprehensive access and capacity. Community hospital laboratories perform 50% of all laboratory tests in this country and have adequate excess capacity to fulfill the remaining community needs.

Mesh:

Year:  1996        PMID: 8653920

Source DB:  PubMed          Journal:  Clin Chem        ISSN: 0009-9147            Impact factor:   8.327


  64 in total

1.  An Analysis of Medical Laboratory Technology Journals' Instructions for Authors.

Authors:  Martina Horvat; Ana Mlinaric; Jelena Omazic; Vesna Supak-Smolcic
Journal:  Sci Eng Ethics       Date:  2015-08-01       Impact factor: 3.525

2.  Multicenter Assessment of Gram Stain Error Rates.

Authors:  Linoj P Samuel; Joan-Miquel Balada-Llasat; Amanda Harrington; Robert Cavagnolo
Journal:  J Clin Microbiol       Date:  2016-02-17       Impact factor: 5.948

3.  The impending crisis.

Authors:  Raymond L Kaplan; Thomas E Burgess
Journal:  J Microbiol Biol Educ       Date:  2010-12-20

4.  Delay in specimen processing-major source of preanalytical variation in serum electrolytes.

Authors:  Ankur Baruah; Parul Goyal; Saket Sinha; K L Ramesh; Rashmirasi Datta
Journal:  J Clin Diagn Res       Date:  2014-12-05

5.  Pending laboratory tests and the hospital discharge summary in patients discharged to sub-acute care.

Authors:  Stacy E Walz; Maureen Smith; Elizabeth Cox; Justin Sattin; Amy J H Kind
Journal:  J Gen Intern Med       Date:  2010-11-30       Impact factor: 5.128

6.  Laboratory Medicine Education at U.S. Medical Schools: A 2014 Status Report.

Authors:  Brian R Smith; Malek Kamoun; John Hickner
Journal:  Acad Med       Date:  2016-01       Impact factor: 6.893

7.  Effect of changing urine testing orderables and clinician order sets on inpatient urine culture testing: Analysis from a large academic medical center.

Authors:  Satish Munigala; Rebecca Rojek; Helen Wood; Melanie L Yarbrough; Ronald R Jackups; Carey-Ann D Burnham; David K Warren
Journal:  Infect Control Hosp Epidemiol       Date:  2019-02-21       Impact factor: 3.254

8.  Sigma Metric Evaluation of Drugs in a Clinical Laboratory: Importance of Choosing Appropriate Total Allowable Error and a Troubleshooting Roadmap.

Authors:  Lokesh Kumar Sharma; Rashmi Rasi Datta; Neera Sharma
Journal:  J Lab Physicians       Date:  2021-05-21

9.  A core curriculum for clinical fellowship training in pathology informatics.

Authors:  David S McClintock; Bruce P Levy; William J Lane; Roy E Lee; Jason M Baron; Veronica E Klepeis; Maristela L Onozato; Jiyeon Kim; Anand S Dighe; Bruce A Beckwith; Frank Kuo; Stephen Black-Schaffer; John R Gilbertson
Journal:  J Pathol Inform       Date:  2012-08-30

10.  The future of genomics in pathology.

Authors:  Dennis P Wall; Peter J Tonellato
Journal:  F1000 Med Rep       Date:  2012-07-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.